Sumitomo Demag nears completion of relocation to larger parts, service facility in Cleveland

MOSCOW (MRC) -- Injection molding machine maker Sumitomo (SHI) Demag Plastics Machinery is nearing the end of its relocation project to move from its plant in Strongsville, Ohio, to a 30,750-square-foot facility in Cleveland, Ohio that will be a dedicated centre for the company’s USD10 million replacement parts inventory and machine rebuilding service, said Canplastics.

Suwanee, Ga.-based Sumitomo Demag said the new Cleveland plant is strategically located adjacent to Cleveland Hopkins International Airport with immediate access to a full range of shipping and transport services. Sumitomo Demag had occupied the Strongsville plant since 1969.

The Strongsville employees performing what the company called “essential operations” have already transitioned to the new facility and will eventually be joined by the ones who are still working remotely. The company has also invested in new equipment at the facility to improve the efficiency of picking, packing. Other services that will be offered at the new facility will include control upgrades, complete barrel assemblies, injection unit repair and rebuilding, manifold rebuilding, electrical cabinet rebuilding, linkage rebuilding, ball screw rebuilding and full assemblies, and OEM legacy and new machine option kits.

The developments in Cleveland cap a busy 12 months for the company, which also opened a new 74,500-square-foot facility in Suwanee, Ga.; a new 15,300-square-foot technology centre outside Chicago in Buffalo Grove, Ill.; and a training and demonstration centre in Anaheim, Calif.

The company had planned on holding a grand opening for the Buffalo Grove site in March with four machine demonstrations, but it was canceled because of the COVID-19 pandemic.

"2019 was a year of extensive U.S. expansion for us," said John F. Martich III, executive vice president and chief operating officer of Sumitomo (SHI) Demag’s U.S. operations. “2020 has focused on investments in infrastructure, logistics and efficiencies. Our Georgia facility, in addition to being the company’s headquarters, has now been improved with the necessary equipment and structural improvements to serve as the centre for our large inventory of U.S.-stocked machines. From a logistics standpoint, the facility is just four hours away from the Port of Savannah which is now the third largest U.S. container port."

As it was written earlier, in July, Sumitomo (SHI) Demag Plastics Machinery completed the expansion and modernisation of its training centre and embarked on the next phase of its growth strategy by breaking ground on a new 1600 m2 warehouse, both at its site in Schwaig, Germany.

As per MRC, Russia's output of products from polymers grew in July 2020 by 3.1% year on year under the pressure of seasonal factors. However, this figure increased by 1.6% year on year in the first seven months of 2020. According to the Russian Federal State Statistics Service, July production of unreinforced and non-combined films rose to 118,200 tonnes from 114,700 tonnes a month earlier. Output of films products grew in January-July 2020 by 9.1% year on year to 736,800 tonnes.
MRC

ATS Automation gets USD20 million order for COVID-19 vaccine syringe manufacturing line

MOSCOW (MRC) -- ATS Automation Tooling Systems has received a USD20 million order from a medical device manufacturer to design, build, and deliver several automated safety syringe manufacturing systems to meet potential demand related to COVID-19 vaccine production, said Canplastics.

The Cambridge, Ont.-based manufacturer, which specializes in custom and repeat automation in a range of industries including life sciences, is developing the systems for a program related to the U.S. government’s Operation Warp Speed initiative, which seeks to increase the ability to produce safety needles and syringes in the U.S.

The automated systems will feature ATS’ new Symphoni digital manufacturing technology, which adds to the productivity of automated assembly processes by eliminating non-value-added production time.

In a statement, ATS said the high degree of standardization, modular building blocks and plug-and-play nature means Symphoni systems are multi-purpose production assets, and have the flexibility to adapt to new products and new processes.

Symphoni systems are 100 per cent programmable, so all movements are precisely mapped out and synchronized through a technique known as electronic gearing, resulting in a “symphony of motion." It meets the manufacturing demands of high-volume consumables such as syringes because it assembles them at very high rates in a compact footprint while assuring compliance to the medical device industry’s rigid quality standards.

"Our teams remain focused on helping manufacturers address the critical need for medical equipment brought on by the COVID-19 pandemic," said ATS CEO Andrew Hider in the statement.

The program will be completed over the next 10 months.

As MRC informed earlier, European Parliament says that the EU should become more self-sufficient in medicines and medical equipment so that affordable treatments are available at any time. It calls for priority to be given to boosting domestic production of essential and strategic medicines because currently 40% of medicines marketed in the EU originate in non-EU countries and 60-80% of its active pharmaceutical ingredient (API) supplies are produced in China and India.

According to MRC's ScanPlast report, Russia's overall PE production totalled 1,712,400 tonnes in the first seven months of 2020, up by 58% year on year. Linear low density polyethylene (LLDPE) accounted for the greatest increase in the output. At the same time, overall PP production in Russia increased in January-July 2020 by 24% year on year to 1,063,700 tonne. ZapSibNeftekhim accounted for the main increase in the output.
MRC

Hengyi plans USD13.65-billion second phase of Brunei project

MOSCOW (MRC) -- China’s Hengyi Petrochemical Co Ltd plans to spend USD13.65 billion to build the second phase of a refinery and petrochemical complex in Brunei, it said on Tuesday in a stock filing, said Reuters.

Hengyi, one of the few private Chinese firms operating a refinery outside China, plans to add a 14 million tonne per year (280,000 barrel per day) crude oil refinery and a two million tpy paraxylene unit at its complex in Palau Muara Besar, the company said.

It will also build a 1.65 million tpy ethylene plant and 2.5 million tpy purified terephthalic acid (PTA) facility. Paraxylene and PTA are key materials for making polyester fibre used in textiles and packaging.

Construction will take three years and the investment is expected to bring an additional annual net profit of about USD1.72 billion, the firm said, without giving a date for starting work.

As MRC informed earlier, Hengyi in 2019 started up a 160,000-bpd refinery and petrochemical facilities at the same site at Palau Muara Besar. The company’s phase I project at the same site started commercial operation in November 2019. It has an 8m tonne/year refining capacity and can produce 1.5m tonnes/year of PX, 500,000 tonnes/year of benzene, and 6m tonnes/year of oil products including gasoline, diesel and kerosene.

According to MRC's ScanPlast report, Russia's overall PE production totalled 1,712,400 tonnes in the first seven months of 2020, up by 58% year on year. Linear low density polyethylene (LLDPE) accounted for the greatest increase in the output. At the same time, overall PP production in Russia increased in January-July 2020 by 24% year on year to 1,063,700 tonne. ZapSibNeftekhim accounted for the main increase in the output.
MRC

BP warns oil demand may have peaked as pandemic hits fossil fuels

MOSCOW (MRC) -- Global oil demand may have already peaked, according to BP's latest long-term energy outlook, as the COVID-19 pandemic kicks the world economy onto a weaker growth trajectory and accelerates the shift to cleaner fuels, reported S&P Global.

Demand for oil will be the biggest casualty over lower energy demand in the coming three decades as weaker economic growth and a faster shift to renewable energy accelerates the demise of oil-based transport fuels, BP said its Energy Outlook 2020 published Sept. 14.

Global demand for liquid fuels, including oil and biofuels, will almost halve to less than 55 million b/d by 2050, when oil's share of the global energy mix will slip to just 14% from around a third currently, according to BP's new central "Rapid" energy transition scenario.

Even under a more conservative "Business as Usual" scenario, BP now sees global oil demand peaking within a few years at just over the 100 million b/d level seen in 2019.

"There is a risk that the economic losses from COVID-19 may be significantly bigger, especially if there are further waves of infection," BP said.

Under its central scenario, BP sees oil demand around 3 million b/d lower in 2025 and 2 million b/d lower in 2050 as a result of the pandemic. About two-thirds of the impact reflects a weaker global economy, with the remaining third a result of lasting behavioral changes due to COVID-19, BP said.

These "scarring effects" from the crisis will see absolute demand for fossil fuels fall in all future scenarios, BP's chief economist Spencer Dale said, marking an "unprecedented" historical decline for any class of fuel in the world's energy mix.

Oil in transport alone will peak in the mid- to late 2020s in all scenarios, Dale said, driven by progress on efficiency and electrification.

Less global air travel and more home-based work could be a lasting legacy of the pandemic, while policy pressure could accelerate the uptake of electric cars, boost recycling and reduce the use of single-use plastics, he said.

"The diminished role for oil reflects the proportionally higher impact of COVID-19 on the transport sector, faster penetration of electricity and hydrogen in transport, and more stringent policy assumptions regarding the use of plastics," BP said in the report.

By 2050, both bioenergy, such as biofuels, and hydrogen will account for around 7% of primary energy consumption, BP's central scenario predicts, and the share of oil in transport slumps to 40% from 90% in 2018.

"...In all our scenarios, the share of renewables energy grows more quickly than any fuel in history," Dale said.

Renewables are set to see their share of the global energy mix jump from 5% in 2018 to 45% in the "Rapid" scenario, led by a jump in wind and solar capacity. Electricity in the energy mix increases from a little over 20% in 2018 to 45%, with 350 GW of new wind and solar growth alone by 2035.

With clean, renewable energy surging, BP sees the role of natural gas lower than in last year's report, squeezed by a more pronounced shift to renewable energy in power generation and a greater substitution by electricity and hydrogen. Gas demand now peaks in the mid-2030s at 26% of the energy mix in the "Rapid" scenario before slipping to 21% by 2050.

BP makes the shift to its new central scenario to "Rapid" after its new CEO Bernard Looney set out ambitious plans for the oil major's pivot to cleaner energy back in February. Europe's number two oil company wants to shrink its oil and gas production by at least 1 million b/d of oil equivalent, or 40%, over the next decade, in a radical transformation.

Under BP's base-case "Evolving Transition" scenario last year, the company saw global liquids demand holding steady at 108 million b/d to 2040, after peaking in 2035.

BP's more pessimistic outlook for oil demand contrasts with the International Energy Agency, which in November predicted oil demand growth would be flattening out by 2030 to reach 106.4 million b/d in 2040.

Speaking in July, the head of the IEA, Fatih Birol, said he "would not be surprised" if global oil demand fully recovers to over 100 million b/d after the pandemic is brought under control.

S&P Global Platts Analytics sees global oil demand peaking in 2040 at around 120 million b/d before slipping to 116.5 million b/d in 2050 under a "most likely" scenario.

Compared to last year's report, BP's renewable energy's share of global energy in 2040 is now 7 percentage points higher, due to higher-than-expected contributions from bioenergy, wind and solar power, supported by "green" hydrogen production.

Under BP's central scenario, carbon emissions fall by around 70% by 2050, driven by high carbon prices and strong climate policy. Under "Business as Usual," carbon emissions fall by around 10% by 2050, having peaked in the mid-2020s as policy and social preferences continue to evolve as in recent years.

Earlier this year, BP said the deadly coronavirus outbreak could cut global oil demand growth by 40 per cent in 2020, putting pressure on Opec producers and Russia to curb supplies to keep prices in check.

And in September 2019, six world's major petrochemical companies in Flanders, Belgium, North Rhine-Westphalia, Germany, and the Netherlands (Trilateral Region) announced the creation of a consortium to jointly investigate how naphtha or gas steam crackers could be operated using renewable electricity instead of fossil fuels. The Cracker of the Future consortium, which includes BASF, Borealis, BP, LyondellBasell, SABIC and Total, aims to produce base chemicals while also significantly reducing carbon emissions. The companies agreed to invest in R&D and knowledge sharing as they assess the possibility of transitioning their base chemical production to renewable electricity.

Ethylene and propylene are feedstocks for producing polyethylene (PE) and polypropylene (PP).

According to MRC's ScanPlast report, Russia's overall PE production totalled 1,712,400 tonnes in the first seven months of 2020, up by 58% year on year. Linear low density polyethylene (LLDPE) accounted for the greatest increase in the output. At the same time, overall PP production in Russia increased in January-July 2020 by 24% year on year to 1,063,700 tonne. ZapSibNeftekhim accounted for the main increase in the output.
MRC

Thermo Fisher investing USD140 million to boost laboratory plastic production for COVID-19 testing

MOSCOW (MRC) -- Scientific instrumentation equipment maker Thermo Fisher Scientific Inc. is investing USD140 million to expand its existing laboratory plastics production to support global demand for COVID-19 testing and the development of therapies and vaccines, said Canplastics.

"Early in the pandemic, we quickly joined forces with governments, public health agencies and industry to increase capacity across our laboratory plastics production facilities and address the growing COVID-19 threat,” said Fred Lowery, senior vice president and president of Life Sciences Solutions and Laboratory Products at Thermo Fisher. “However, demand quickly exceeded those early expansion projects, so we began a series of additional expansions to meet the growing needs of our customers. These investments, along with many others across the company, will ensure that our customers have the supplies they need to continue meeting the unprecedented demands of the COVID-19 response."

The rapid increase in production related to COVID-19 testing, and development and manufacturing of therapies and vaccines, has created what the company calls “historic demand for laboratory plastics”, including pipette and automation tips, storage tubes and plates, transfer pipettes, and packaging vials and bottles. To support these needs, Waltham, Mass.-based Thermo Fisher is creating more than 1,000 jobs across manufacturing sites globally, increasing automation capabilities, and optimizing warehouse and sterilization capacity to improve supply chain agility.

Among the Thermo Fisher sites currently being expanded are Rochester, N.Y.; Petaluma, Calif.; Monterrey and Tijuana, Mexico; and Joensuu, Finland.

This latest investment comes on the heels of Thermo Fisher’s opening last month of a new US$40 million facility in Lenexa, Kan., for viral transport media production to meet sustained demand for COVID-19 testing.

As MRC informed earlier, European Parliament says that the EU should become more self-sufficient in medicines and medical equipment so that affordable treatments are available at any time. It calls for priority to be given to boosting domestic production of essential and strategic medicines because currently 40% of medicines marketed in the EU originate in non-EU countries and 60-80% of its active pharmaceutical ingredient (API) supplies are produced in China and India.

According to MRC's ScanPlast report, Russia's overall PE production totalled 1,712,400 tonnes in the first seven months of 2020, up by 58% year on year. Linear low density polyethylene (LLDPE) accounted for the greatest increase in the output. At the same time, overall PP production in Russia increased in January-July 2020 by 24% year on year to 1,063,700 tonne. ZapSibNeftekhim accounted for the main increase in the output.
MRC